مباشر
FierceBiotechAgenus focuses on survival data as 0% response rate triggers primary missFierceBiotechOdyssey charts fresh voyage to public markets after abandoning IPO plans last yearFierceBiotechAstraZeneca’s faith in IL-33 inhibitor continues to pay off with latest phase 3 COPD winMedtronicWire-free artery assessment tech joins Medtronic in $585M deal - Stock TitanMedtronicPulnovo completes $100m financing round with Medtronic investment - Yahoo FinancePfizerPfizer, Astellas win FDA priority review for Padcev (PFE:NYSE) - Seeking AlphaMedtronicMedtronic, Pulnovo Join Forces On Pulmonary Denervation After $100M Financing - Citeline News & InsightsMedtronicPulnovo Medical: $100 Million Raised From Medtronic For Pulmonary Hypertension And Heart Failure Therapies - Pulse 2.0Merck & Co.TD Waterhouse Canada Inc. Grows Holdings in Merck & Co., Inc. $MRK - MarketBeatSiemens HealthineersScreenPoint Medical raises $16m with continued investment from Siemens Healthineers - Medical Device NetworkMedtronicMedtronic leads $100M financing for artery denervation tech developer Pulnovo Medical - MassDeviceWuXi AppTecHow WuXi AppTec’s Integrated Platform Is Helping Therapies Move Faster from Discovery to Patients - Fierce Biotech
BioWorld ٢٧ فبراير ٢٠٢٦

Prospect Therapeutics identifies new JAK1 and TYK2 inhibitors

Prospect Therapeutics identifies new JAK1 and TYK2 inhibitors

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.